Trial Profile

Phase III study of gefitinib versus erlotinib in patients with previously treated lung adenocarcinoma.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Gefitinib (Primary)
Indications Adenocarcinoma; Lung cancer
Focus Therapeutic Use

Most Recent Events

28 Mar 2016 Results published in the Journal of Clinical Oncology.
17 Oct 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
31 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com